Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Francis Gleeson
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
- Beta
- 0.71
- Country
- CA
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 15.07
Financials
Net Income
$-7.30MEBITDA
$-7.65MFree Cash Flow
$-7.26MEPS (diluted)
$-6.00Shares Outstanding (diluted)
1.22M-71.2%Operating Expenses
$7.49MCash & Debt
$27.71MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-24.87M | $-20.40 |
| 2024 | $0.00 | $-28.1K | $-0.00 |
| 2023 | $0.00 | $-15.9K | $-0.00 |
| 2022 | $0.00 | $-11.32M | $-3.80 |
| 2021 | $0.00 | $-15.51M | $-7.68 |
| 2020 | $0.00 | $-1.58M | $-0.58 |
| 2019 | $0.00 | $-1.94M | $-0.33 |
| 2018 | $0.00 | $-1.70M | $-0.41 |
| 2017 | $0.00 | $-1.26M | $-0.20 |
| 2016 | $0.00 | $-1.50M | $-0.41 |
| 2015 | $0.00 | $-1.79M | $-0.40 |
| 2014 | $0.00 | $-1.92M | $-0.39 |
| 2013 | $0.00 | $-5.38M | $-1.70 |
| 2012 | $0.00 | $-3.65M | $-1.41 |
Valuation
MSCLFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+11.11%Social Signal Score
Mentions (6)
- Newsglobenewswire.com·1d ago·Neutral
Satellos Granted Composition of Matter Patent for Forazapadin Composition of matter provides U.S. protection through Sept. 6, 2044, as forazapadin advances in Phase 2 development Composition of matter provides U.S. protection through Sept. 6, 2044, as forazapadin advances in Phase 2 development
View source ↗ - Newsglobenewswire.com·6d ago·Negative
Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy TORONTO, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced that enrollment has been completed for BASECAMP, the company's Phase 2 clinical trial evaluating forazapadin for the treatment of Duchenne muscul
View source ↗ - Newsglobenewswire.com·12d ago·Negative
Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing potentially life-improving medicines to treat degenerative muscle diseases, today announced that the U.S. Food and Drug Adm
View source ↗ - Newsglobenewswire.com·27d ago·Negative
Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247 TORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience (Nasdaq: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced the assignment of the International Nonproprietary Name (INN) “forazapadin” for the Company's orally administered, small molecule drug candidate designed to restore
View source ↗ - Newsglobenewswire.com·35d ago·Negative
Satellos to Participate in Upcoming Investor Conferences TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced that management will participate in the following investor conferences in September.
View source ↗ - Newsglobenewswire.com·53d ago·Negative
Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced financial results for the second quarter ended June 30, 2026. The company also provided an update on the clinical development program for SAT-3247, an orally administered, small molecul
View source ↗
Earnings
Typical surprise +1.1% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Mar 27$-6.00 vs $-0.03miss
- Fri, Nov 14$-0.03 vs $-0.03miss
- Wed, Aug 13$-0.02 vs $-0.02beat
- Tue, May 13$-0.04 vs $-0.03miss
- Wed, Mar 26$-0.01 vs $-0.05beat
- Wed, Nov 13$-0.05 vs $-0.07beat
Estimates and results for MSCLF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in MSCLF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.